The Comprehensive Cancer Center Zurich cooperates with numerous organizations, societies and institutes in Switzerland and abroad. In collaboration with our partners, we aim to improve the diagnostic and treatment options for cancer patients.
Over 50 years ago, visionary leaders in cancer medicine realized that advancement of patient management requires solid understanding of the disease and biology, vigorous testing of novel treatments, and interdisciplinary collaboration and exchange beyond state boundaries. This remains true today, and is even more important as we move into an era of personalized medicine.
The “Organisation of European Cancer Institutes” is a non-governmental, no-profit legal Entity established in 1979 to promote greater cooperation among European Cancer Centres and Institutes.
Its founders designed a structure aimed at promoting efficient partnership across Europe, notwithstanding its linguistic barriers and traditional care and research heterogeneity.
The OECI is a network collaborating to reduce fragmentation and to give to all European cancer patients the possibility of receiving the best available care.
ESMO’s core mission is to improve the quality of cancer care, from prevention and diagnosis all the way to palliative care and patient follow-up. It is to educate – doctors, cancer patients and the general public – on the best practices and latest advances in oncology. And it is to promote equal access to optimal cancer care for all patients.
The European Thoracic Oncology Platform (ETOP) is a foundation promoting exchange and research in the field of thoracic malignancies in Europe. It is a not-for-profit organization, domiciled in Bern, Switzerland. Since 2009 ETOP has continuously enlarged its membership and now comprises more than 50 collaborative groups and institutions from all over Europe and beyond.
IBCSG is dedicated to innovative clinical cancer research designed to improve the outcome of women with breast cancer. The goal of clinical research within IBCSG is to find answers to key questions. We wish to give our patients a longer survival, if we fail to cure, a longer symptom free period after the primary treatment and eventually to improve their quality of life.
The Paul Scherrer Institute PSI is the largest research center for natural and engineering sciences in Switzerland. We conduct cutting-edge research in the fields of matter and materials, people and health, and energy and the environment. Through basic and applied research, we work on sustainable solutions for key issues in society, business and science.
Since 1980, the Canton of Zurich has maintained an epidemiological cancer registry at the Institute of Pathology and Molecular Pathology of the University Hospital Zurich in close collaboration with the Institute of Epidemiology, Biostatistics and Prevention of the University of Zurich, which has the task of recording as many new cases of cancer as possible in the population of the canton. Its core mission is to monitor the cancer burden in the population. This includes systematic and continuous data collection, analysis, comparison or interpretation of data, and dissemination of results through reporting.
The Swiss Association for Clinical Cancer Research (SAKK) is committed to clinical cancer research as a profit-independent organization. Its most important goal is to research new cancer therapies and further develop existing treatments, taking into account all therapeutic modalities, and to improve the chances of recovery for patients with cancer. This is done through collaborations within Switzerland and in cooperation with foreign centers and study groups.